JPMorgan Chase & Co. Lowers IQVIA (NYSE:IQV) Price Target to $239.00

IQVIA (NYSE:IQV) had its target price cut by analysts at JPMorgan Chase & Co. from $262.00 to $239.00 in a research note issued on Monday, Benzinga reports. The firm currently has an “overweight” rating on the medical research company’s stock. JPMorgan Chase & Co.‘s target price would indicate a potential upside of 19.23% from the company’s previous close.

A number of other brokerages also recently commented on IQV. Citigroup increased their price target on shares of IQVIA from $200.00 to $225.00 and gave the company a “neutral” rating in a report on Wednesday, August 2nd. HSBC started coverage on shares of IQVIA in a report on Wednesday, September 6th. They issued a “buy” rating and a $260.00 price objective for the company. Robert W. Baird cut IQVIA from an “outperform” rating to a “neutral” rating and cut their price target for the company from $248.00 to $202.00 in a report on Thursday, November 2nd. Truist Financial decreased their price target on shares of IQVIA from $260.00 to $240.00 and set a “buy” rating for the company in a research report on Friday, November 3rd. Finally, Morgan Stanley cut their target price on IQVIA from $240.00 to $225.00 and set an “overweight” rating on the stock in a research report on Friday, November 3rd. Three analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $236.57.

IQVIA Stock Up 3.5 %

Shares of NYSE:IQV opened at $200.46 on Monday. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.79 and a quick ratio of 0.79. The stock’s 50-day moving average is $198.14 and its 200 day moving average is $207.02. IQVIA has a 1 year low of $167.42 and a 1 year high of $241.86. The company has a market cap of $36.58 billion, a PE ratio of 33.69, a P/E/G ratio of 2.53 and a beta of 1.42.

Insider Buying and Selling

In other IQVIA news, insider Constantinos Panagos sold 27,317 shares of IQVIA stock in a transaction dated Tuesday, September 19th. The stock was sold at an average price of $208.67, for a total transaction of $5,700,238.39. Following the transaction, the insider now owns 14,250 shares of the company’s stock, valued at approximately $2,973,547.50. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 1.50% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On IQVIA

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. ST Germain D J Co. Inc. bought a new stake in IQVIA in the second quarter valued at $33,000. AllSquare Wealth Management LLC acquired a new stake in shares of IQVIA in the first quarter valued at approximately $36,000. Financial Gravity Asset Management Inc. acquired a new stake in shares of IQVIA in the first quarter valued at approximately $1,989,000. Live Oak Investment Partners acquired a new stake in IQVIA during the 4th quarter worth approximately $41,000. Finally, Headlands Technologies LLC increased its stake in IQVIA by 62.3% during the 1st quarter. Headlands Technologies LLC now owns 224 shares of the medical research company’s stock worth $45,000 after acquiring an additional 86 shares during the period. 86.82% of the stock is currently owned by institutional investors and hedge funds.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.